Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endeavor Resolute approved in EU:

This article was originally published in Clinica

Executive Summary

Medtronic, of Minneapolis, Minnesota, has CE-marked the new form of its zotarolimus-eluting Endeavor stent for sale in the EU, enabling the device's launch in various non-US countries earlier than the company had originally expected. The Endeavor Resolute stent will be launched in more than 50 countries in Europe, Asia, the Middle East and Africa by the end of this year. The new stent is not approved in the US; the first-generation form of the device is expected to gain US approval by the end of 2007. Endeavor Resolute uses a biocompatible polymer called BioLinx, designed to extend the duration of drug exposure in the vessel.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel